HistoGeneX
CellCarta is a global Contract Research Organization (CRO) dedicated to advancing precision medicine through a comprehensive suite of biomarker and laboratory services. With a mission to support the entire drug development cycle—from discovery to clinical phases—and a vision to transform healthcare outcomes worldwide, CellCarta leverages cutting-edge technologies and a global presence to deliver customized, high-quality solutions. The company emphasizes scientific excellence, regulatory compliance, and innovative approaches to biomarker discovery, validation, and testing across oncology, immunology, infectious diseases, and more.
Industries
Nr. of Employees
medium (51-250)
Products
Healthy tissue reference database
Curated database of healthy tissue antigen and peptide profiles used to contextualize antigen presentation and support neo-epitope prioritization during discovery.
Cytometry analysis platform
Software platform for standardized processing, automated analysis, visualization and reporting of flow and mass cytometry data to support research and clinical workflows.
Healthy tissue reference database
Curated database of healthy tissue antigen and peptide profiles used to contextualize antigen presentation and support neo-epitope prioritization during discovery.
Cytometry analysis platform
Software platform for standardized processing, automated analysis, visualization and reporting of flow and mass cytometry data to support research and clinical workflows.
Services
Statistical analysis, machine learning and bioinformatics pipelines for proteomic, genomic and cytometry datasets, with standardized and customizable reporting guided by statistical analysis plans.
Cloud-enabled software platform for processing, automated analysis, visualization and reporting of flow and mass cytometry experiments.
Assay development and regulatory-transition support for diagnostics and companion diagnostic applications.
Tissue imaging and multiplex IHC/IF workflows combined with pathologist review and quantitative image analysis to support biomarker scoring and pathology reporting.
Molecular testing services including digital PCR, qPCR, bulk and single-cell RNA sequencing and NGS workflows for mutation and expression profiling.
Clinical-grade histopathology including IHC, IF and ISH, with multiplex tissue assays and pathologist-led reporting for clinical and translational studies.
Statistical analysis, machine learning and bioinformatics pipelines for proteomic, genomic and cytometry datasets, with standardized and customizable reporting guided by statistical analysis plans.
Cloud-enabled software platform for processing, automated analysis, visualization and reporting of flow and mass cytometry experiments.
Assay development and regulatory-transition support for diagnostics and companion diagnostic applications.
Tissue imaging and multiplex IHC/IF workflows combined with pathologist review and quantitative image analysis to support biomarker scoring and pathology reporting.
Molecular testing services including digital PCR, qPCR, bulk and single-cell RNA sequencing and NGS workflows for mutation and expression profiling.
Clinical-grade histopathology including IHC, IF and ISH, with multiplex tissue assays and pathologist-led reporting for clinical and translational studies.
Expertise Areas
- Biomarker development and validation
- Immune monitoring and cellular phenotyping
- Proteomics and targeted mass spectrometry
- Genomics and transcriptomics (bulk and single-cell)
Key Technologies
- Multiparametric flow cytometry
- Mass cytometry (CyTOF)
- Targeted mass spectrometry (MRM/targeted MS)
- Multiplex immunoassays (high-throughput platforms)
News & Updates
Discussion on antibody-drug conjugates and their development.
Advancing precision diagnosis and treatment through partnership.
Launch of new digital platforms for better customer engagement.
Importance of integrated antibody and cellular immunity monitoring.
Leadership update in 2025.
Discussion on antibody-drug conjugates and their development.
Advancing precision diagnosis and treatment through partnership.
Launch of new digital platforms for better customer engagement.
Importance of integrated antibody and cellular immunity monitoring.
Leadership update in 2025.